Prediction of prostate cancer by deep learning with multilayer artificial neural network.

INTRODUCTION To predict the rate of prostate cancer detection on prostate biopsy more accurately, the performance of deep learning using a multilayer artificial neural network was investigated. METHODS A total of 334 patients who underwent multiparametric magnetic resonance imaging before ultrasonography guided transrectal 12-core prostate biopsy were enrolled in the analysis. Twenty-two non-selected variables, as well as selected ones by least absolute shrinkage and selection operator (Lasso) regression analysis and by stepwise logistic regression analysis, were input into the constructed multilayer artificial neural network (ANN) programs; 232 patients were used as training cases of ANN programs and the remaining 102 patients were for the test to output the probability of prostate cancer existence, accuracy of prostate cancer prediction, and area under the receiver operating characteristic (ROC) curve with the learned model. RESULTS With any prostate cancer objective variable, Lasso and stepwise regression analyses selected 12 and nine explanatory variables, respectively, from 22. Using trained ANNs with multiple hidden layers, the accuracy of predicting any prostate cancer in test samples was about 5-10% higher compared to that with logistic regression analysis (LR). The area under the curves (AUC) with multilayer ANN were significantly larger on inputting variables that were selected by the stepwise LR compared with the AUC with LR. The ANN had a higher net benefit than LR between prostate cancer probability cutoff values of 0.38 and 0.6. CONCLUSIONS ANN accurately predicted prostate cancer without biopsy marginally better than LR. However, for clinical application, ANN performance may still need improvement.

[1]  Osamu Ukimura,et al.  A Randomized Controlled Trial To Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy. , 2016, European urology.

[2]  W. Ellis,et al.  Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. , 2013, European urology.

[3]  M. Barry,et al.  Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. , 2007, Journal of the National Cancer Institute.

[4]  M. Kattan,et al.  Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. , 2008, The Journal of urology.

[5]  R. Tibshirani Regression Shrinkage and Selection via the Lasso , 1996 .

[6]  A. Haese*,et al.  Development and external validation of an extended repeat biopsy nomogram. , 2007, The Journal of urology.

[7]  M. Kattan,et al.  Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information. , 2011, Urology.

[8]  G. Haber,et al.  Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging‐targeted and systematic biopsy for significant prostate cancer detection , 2011, BJU international.

[9]  M. Melissari,et al.  A novel nomogram to predict the probability of prostate cancer on repeat biopsy. , 2008, The Journal of urology.

[10]  A. Rosenkrantz,et al.  Prediction of Prostate Cancer Risk Among Men Undergoing Combined MRI-targeted and Systematic Biopsy Using Novel Pre-biopsy Nomograms That Incorporate MRI Findings. , 2017, Urology.

[11]  M. Kattan,et al.  A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. , 2009, The Journal of urology.

[12]  J. Fütterer,et al.  Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. , 2013, European urology.

[13]  R. Faletti,et al.  Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer. , 2017, European urology.